|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Community Acquired Respiratory Tract Infections - Room for Ketek?
Datamonitor, March 2004, Pages: 203
Introduction
Aventis' novel antibacterial Ketek is the first in a new class, the ketolides. It has already been launched in a number of European regions but is yet to achieve FDA approval in the US. However, this is anticipated early in 2004. The use of this product and its eventual success will depend heavily on physician perception of this product, with safety and its potential for pediatric use being key.
Scope
-Analysis based on interviews with key opinion leaders in the major markets
-Community respiratory tract infection (RTI) market definition and assessment of relative importance to total antibacterial sector
-Individual RTI therapies are compared, with an assessment of presentation routes and referral patterns and their impact on treatment decisions
-In-depth evaluation of the potential of the new ketolide class and most notably Aventis’s Ketek
Report Highlights
Respiratory tract infections led to 174,000 deaths in Europe and 3.8 million worldwide, accounting for 6% of the global and 1.3% of European disease burden (World Health Report, 2003). As a result, RTIs are responsible for the most significant proportion of community-based antibacterial prescriptions in Europe (36% - IMS Health, 2003).
While the majority of RTI patients initially present to their GP/PCP, there are other routes of access to medical care, such as ‘drop-in centers’, community-based experts and the emergency room. Companies will need to adopt region-specific marketing strategies and develop innovative ways of reaching a wider proportion of the prescribing population.
Resistant pathogens pose a growing threat in the community management of RTIs. The perceived seriousness of this dynamic varies not only according to market, but type of prescribing physician so affecting promotional strategies and continued uptake of newer therapeutic options.
Reasons to Purchase
Improve promotional efficiency for community acquired RTI therapies, through greater understanding of presentation and referral patterns
Gain expert insight into the advantages and disadvantages of competing therapies for the treatment of RTIs
Understand fully the potential impact of the novel ketolide class and predict the success of Aventis’s Ketek
Customers who bought this item also bought
Stakeholder Opinions: Urinary Tract Infections - Ciprofloxacin Leads the Way
Stakeholder Insight: The Hospital Antibacterial Market - Specialist Products Drive Market Growth
Stakeholder Opinions: Skin Infections - Where In The Antibacterial Lifecycle?
Bacterial Infections: An Epidemiological Overview
Bacterial Infections: An Epidemiological Overview
Stakeholder Insight: Invasive Fungal Infections - Options Outweigh Replacements
Stakeholder Opinions: HIV/ HBV Co-infection - More Potency, More Policy
Commercial Perspectives: Fluoroquinolones - Established Products Drive Market Growth
|
|
|
|
